Skip to content

Durata Therapeutics, Inc.: 10-K filed 2013-03-08

What Durata Therapeutics, Inc. reported in its annual report filed 2013-03-08 (fiscal FY 2012): 32 published measures, 132 facts as tagged in accession 0001193125-13-097202.

This filing

Form
10-K (annual report)
Filed
2013-03-08
Fiscal period
fiscal FY 2012
Accession
0001193125-13-097202 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Durata Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-12-3186,548,213USD
At 2011-12-3133,624,816USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2012-12-3142,675,761USD
At 2011-12-3122,064,821USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-12-3143,872,452USD
At 2011-12-315,559,995USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-12-3132,257,170USD
At 2011-12-3111,485,266USD
At 2010-12-312,264,145USD
At 2009-12-313,625,497USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-62,538,863USD366
2009-11-05 to 2012-12-31-107,300,171USD1153
2011-01-01 to 2011-12-31-33,033,073USD365
2010-01-01 to 2010-12-31-11,013,860USD365
2009-11-05 to 2009-12-31-714,375USD57

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2012-01-01 to 2012-12-31719,188USD366
2009-11-05 to 2012-12-31719,188USD1153

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-01-01 to 2012-12-3193,445,744USD366
2009-11-05 to 2012-12-31149,222,680USD1153
2011-01-01 to 2011-12-3136,578,999USD365
2010-01-01 to 2010-12-315,197,945USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-14,662,839USD366
2009-11-05 to 2012-12-31-24,703,119USD1153
2010-01-01 to 2010-12-31-40,280USD365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2009-11-05 to 2012-12-315,811,000USD1153
2011-10-01 to 2011-12-311,022,008USD92
2011-01-01 to 2011-12-312,510,653USD365
2011-07-01 to 2011-09-30706,356USD92
2011-04-01 to 2011-06-30605,700USD91
2011-01-01 to 2011-03-31176,589USD90
2010-01-01 to 2010-12-312,878,440USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-12-31981,421USD
At 2011-12-310USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2012-01-01 to 2012-12-311,405,576USD366
2009-11-05 to 2012-12-312,528,943USD1153
2011-01-01 to 2011-12-31781,407USD365
2010-01-01 to 2010-12-31333,903USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2012-10-01 to 2012-12-3113,341,772USD92
2012-01-01 to 2012-12-3162,579,710USD366
2009-11-05 to 2012-12-31113,169,898USD1153
2012-07-01 to 2012-09-3021,785,724USD92
2012-04-01 to 2012-06-3019,192,255USD91
2012-01-01 to 2012-03-318,259,959USD91
2011-10-01 to 2011-12-3110,794,785USD92
2011-01-01 to 2011-12-3135,559,082USD365
2011-07-01 to 2011-09-3010,094,936USD92
2011-04-01 to 2011-06-3012,067,559USD91
2011-01-01 to 2011-03-312,601,802USD90
2010-01-01 to 2010-12-3113,894,824USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-12-3151,195,451USD
At 2011-12-3112,481,536USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-12-3121,500,815USD
At 2011-12-313,325,821USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2012-12-318,617,978USD
At 2011-12-311,956,572USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2012-12-315,811,000USD
At 2011-12-315,811,000USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-10-01 to 2012-12-319,439,736USD92
2012-01-01 to 2012-12-3151,694,722USD366
2009-11-05 to 2012-12-3186,843,648USD1153
2012-07-01 to 2012-09-3018,956,271USD92
2012-04-01 to 2012-06-3016,527,952USD91
2012-01-01 to 2012-03-316,770,763USD91
2011-10-01 to 2011-12-319,038,820USD92
2011-01-01 to 2011-12-3130,132,564USD365
2011-07-01 to 2011-09-308,325,872USD92
2011-04-01 to 2011-06-308,439,070USD91
2011-01-01 to 2011-03-314,328,802USD90
2010-01-01 to 2010-12-314,818,049USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-12-3118,360,459shares
At 2011-12-3162,500shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-12-31150,989,018USD
At 2011-12-3149,828,699USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2012-12-3143,872,452USD
At 2011-12-315,559,995USD
At 2010-12-311,811,662USD
At 2009-12-317,292,580USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2012-12-31996,016USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2012-12-3114,595USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2011-12-3140,280USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2012-12-3110,601,613USD
At 2011-12-311,369,249USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2012-12-315,844,630USD
At 2011-12-31996,270USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2012-10-01 to 2012-12-3113,319,408USD92
2012-01-01 to 2012-12-3162,538,863USD366
2009-11-05 to 2012-12-31113,111,171USD1153
2012-07-01 to 2012-09-3021,774,192USD92
2012-04-01 to 2012-06-3019,187,753USD91
2012-01-01 to 2012-03-318,257,510USD91
2011-10-01 to 2011-12-3110,790,857USD92
2011-01-01 to 2011-12-3135,543,726USD365
2011-07-01 to 2011-09-3010,092,813USD92
2011-04-01 to 2011-06-3012,062,793USD91
2011-01-01 to 2011-03-312,597,263USD90
2010-01-01 to 2010-12-3113,892,300USD365

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2012-10-01 to 2012-12-3113,319,408USD92
2012-01-01 to 2012-12-31-62,538,863USD366
2009-11-05 to 2012-12-31-107,300,171USD1153
2012-07-01 to 2012-09-3021,774,192USD92
2012-04-01 to 2012-06-3019,187,753USD91
2012-01-01 to 2012-03-318,257,510USD91
2011-10-01 to 2011-12-319,768,849USD92
2011-01-01 to 2011-12-31-33,033,073USD365
2011-07-01 to 2011-09-309,386,457USD92
2011-04-01 to 2011-06-3011,457,093USD91
2011-01-01 to 2011-03-312,420,674USD90
2010-01-01 to 2010-12-31-11,013,860USD365

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-62,538,863USD366
2009-11-05 to 2012-12-31-107,300,171USD1153
2011-01-01 to 2011-12-31-33,033,073USD365
2010-01-01 to 2010-12-31-11,013,860USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-10-01 to 2012-12-313,622,036USD92
2012-01-01 to 2012-12-319,787,988USD366
2009-11-05 to 2012-12-3117,782,250USD1153
2012-07-01 to 2012-09-302,552,453USD92
2012-04-01 to 2012-06-302,392,303USD91
2012-01-01 to 2012-03-311,221,196USD91
2011-10-01 to 2011-12-31991,965USD92
2011-01-01 to 2011-12-314,305,518USD365
2011-07-01 to 2011-09-301,009,064USD92
2011-04-01 to 2011-06-301,252,489USD91
2011-01-01 to 2011-03-311,052,000USD90
2010-01-01 to 2010-12-312,776,775USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2012-01-01 to 2012-12-3114,595USD366

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2009-11-05 to 2012-12-31-5,811,000USD1153
2011-01-01 to 2011-12-31-2,510,653USD365
2010-01-01 to 2010-12-31-2,878,440USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2012-01-01 to 2012-12-316,384,578USD366
2009-11-05 to 2012-12-318,341,150USD1153
2011-01-01 to 2011-12-311,250,311USD365
2010-01-01 to 2010-12-31700,705USD365

Inspect the source

Entity
Durata Therapeutics, Inc. / CIK 0001544116
Captured
SEC response SHA-256
b772cae7e439db4bda19a5aa54cd67ad4687936868a9d88fefea11e70429dd01

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001544116.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))